



## **Fibriant and Biomed Elements Combine Strengths to Develop a Novel Haemostasis Product**

**Leiden, The Netherlands, January 5<sup>th</sup> 2017** - Fibriant B.V., a developer of innovative Fibrinogen technology and Biomed Elements B.V., an expert on biopolymer formulation technology for medical application, today announced that they have entered into a collaboration to develop a new haemostat product that can stop life threatening bleeding. The collaboration is supported by a MIT grant from the province of Zuid-Holland that enables the companies to deliver proof of concept of a first-in-class topical haemostat product for severe bleeding.

The versatility of Fibriant's technology platform enables the company to select and manufacture a specific recombinant fibrinogen variant with optimal haemostatic properties for a topical product to address severe bleeding.

The Biomed's Core Technology provides the opportunity to tune the functional characteristics of biopolymers such as gelatine, collagen and hyaluronic acid and make it suitable for its specific application.

Jaap Koopman, Ph.D., Founder and Chief Executive Officer of Fibriant said: "Severe, uncontrollable bleeding is an unmet medical need and an important cause of death following traumatic injuries. The combination of our technologies creates a very potent product because it works through different complementary mechanisms-of-action to stop severe bleeding."

"We believe that a haemostatic product that is readily available in a pre-hospital setting and is capable of controlling severe bleeding is a valuable addition to the toolbox of first responders, paramedics and trauma surgeons and represents a significant commercial opportunity" says Tonny Voermans, Managing Director of Biomed Elements.

### **About Fibriant ([www.Fibriant.com](http://www.Fibriant.com))**

Fibriant was founded in 2015 and is headquartered in Leiden, The Netherlands. The company leverages its expertise in fibrinogen technology to develop innovative healthcare solutions. Human fibrinogen plays a pivotal role in blood clotting, tissue repair, and host defence mechanisms. Fibriant is led by a team with extensive scientific, product development and business experience. The company's core activity is the manufacturing, and characterization of specific variants of fibrinogen. The company has a hybrid business model, using the fibrinogen technology platform for internal product and lead development as well as supporting product development of third parties.

### **About Biomed Elements ([www.biomed-elements.com](http://www.biomed-elements.com))**

BioMed Elements was founded in 2016 with its office in Nijmegen, the Netherlands. BioMed is a subsidiary of FutureChemistry Holding, a leading chemical company in

developing custom made flow chemistry instruments. BioMed has a proprietary technology of tuning the characteristics of biopolymers based on flow chemistry thereby tailoring specifications, the BioMed Core Technology. BioMed has the capability of formulating, developing and manufacturing biomaterials. The biomaterials can be used in wound management, aesthetics, orthopaedics and ENT surgery. BioMed is active in contract research and manufacturing as well as developing niche products in the aforementioned segments.

**Fibriant B.V.**

Jaap Koopman, Ph.D., CEO

Tel: + 31 6 21628475

E-mail: [j.koopman@fibriant.com](mailto:j.koopman@fibriant.com)

**Biomed Elements B.V.**

Tonny Voermans, Managing Director

Tel: +31 6 24194073

E-mail: [t.voermans@biomed-elements.com](mailto:t.voermans@biomed-elements.com)